ETV2 and cancer: As ETV2 has been shown to have a role in cancer (82, 88, 98, 123), understanding whether its ability to remodel silent/compacted chromatin as a pioneer factor has important implications during angiogenesis, as therapeutic initiatives could target and inhibit ETV2 thereby impacting tumorigenesis (82, 98, 123).